<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04505826</url>
  </required_header>
  <id_info>
    <org_study_id>OP-1250-001</org_study_id>
    <nct_id>NCT04505826</nct_id>
  </id_info>
  <brief_title>A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer</brief_title>
  <official_title>A Phase I/II Open-label, First-in-Human, Multicenter, Dose Escalation and Dose Expansion Study of OP-1250 Monotherapy in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olema Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Olema Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is a Phase 1-2, open-label, multi-center, dose-escalation and expansion&#xD;
      study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of&#xD;
      daily oral administration of OP-1250.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OP-1250 is a small molecule Complete Estrogen Receptor ANtagonist (CERAN). OP-1250 potently&#xD;
      competes with the endogenous activating estrogenic ligand 17-beta estradiol for binding in&#xD;
      the ligand binding pocket. OP-1250 blocks estrogen-driven transcriptional activity, inhibits&#xD;
      estrogen-driven breast cancer cell growth, and induces degradation of the estrogen receptor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine MTD and/or RP2D of OP-1250 when used as a single agent</measure>
    <time_frame>Up to one year</time_frame>
    <description>Number of patients with DLT as defined in the protocol</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Hormone Receptor Positive Breast Carcinoma</condition>
  <condition>HER2-negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>OP-1250 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This portion of the study will evaluate the safety and pharmacology of a range of OP-1250 doses administered daily in subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer and to determine the RP2D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OP-1250 Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This portion of the study further explores the clinical activity, safety and pharmacology of OP-1250 monotherapy at the RP2D and to estimate preliminary data of anti-tumor efficacy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OP-1250</intervention_name>
    <description>Complete Estrogen Receptor ANtagonist (CERAN)</description>
    <arm_group_label>OP-1250 Dose Escalation</arm_group_label>
    <arm_group_label>OP-1250 Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Must not have received prior oral endocrine therapy &gt; 2 weeks prior to first dose&#xD;
&#xD;
          -  Must not have received prior fulvestrant, chemotherapy, antibody therapy, or&#xD;
             investigational therapy â‰¤ 4 weeks prior to the first dose&#xD;
&#xD;
          -  Adequate hepatic function&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Normal coagulation panel&#xD;
&#xD;
          -  Willingness to use effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gastrointestinal disease&#xD;
&#xD;
          -  Significant renal disease&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
          -  Significant ECG abnormalities&#xD;
&#xD;
          -  Ongoing systemic bacterial, fungal, or viral infection (requiring antimicrobial&#xD;
             therapy)&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jo Anne Zujewski, MD</last_name>
    <role>Study Director</role>
    <affiliation>Olema Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trinh Le</last_name>
    <role>Study Director</role>
    <affiliation>Olema Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial.</last_name>
    <phone>(415) 651-7206</phone>
    <email>clinical@olemapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Advent Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Center</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Macquarie University</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICON Cancer Centre</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Research South Australia</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

